Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Drops By 53.2%
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Drops By 53.2%
Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 496,400 shares, a drop of 53.2% from the November 30th total of 1,060,000 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average daily volume of 94,500 shares, the short-interest ratio is presently 5.3 days.
AURA生物科學公司(納斯達克:AURA-GET評級)是12月份空頭股數價格大幅下降的接受者。截至12月15日,空頭股數共有49.64萬股,與11月30日的106萬股相比,下降了53.2%。目前,該公司2.8%的股份被賣空。以日均成交量94,500股計算,目前短息比率為5.3天。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, JMP Securities upped their price objective on shares of Aura Biosciences from $26.00 to $30.00 and gave the stock a "market outperform" rating in a research report on Friday, November 11th.
另外,JMP證券在11月11日星期五的一份研究報告中將Aura Biosciences的股票目標價從26.00美元上調至30.00美元,並給予該股“市場表現優於大盤”的評級。
Aura Biosciences Stock Performance
AURA生物科學公司股票表現
AURA stock traded up $0.24 during mid-day trading on Friday, reaching $10.60. 452 shares of the company's stock were exchanged, compared to its average volume of 129,560. Aura Biosciences has a 12-month low of $9.43 and a 12-month high of $24.83. The stock's 50 day moving average is $12.51 and its 200 day moving average is $13.87.
AURA股票在週五午盤交易中上漲0.24美元,達到10.60美元。該公司股票成交量為452股,而其平均成交量為129,560股。Aura Biosciences的12個月低點為9.43美元,12個月高位為24.83美元。該股的50日移動均線切入位在12.51美元,200日移動均線切入位在13.87美元。
Insider Buying and Selling
內幕買賣
In other Aura Biosciences news, major shareholder Matrix Capital Management Comp purchased 1,250,000 shares of the stock in a transaction on Monday, December 5th. The shares were bought at an average cost of $12.00 per share, with a total value of $15,000,000.00. Following the completion of the acquisition, the insider now owns 5,362,870 shares in the company, valued at $64,354,440. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director David Michael Johnson bought 10,000 shares of the business's stock in a transaction dated Thursday, December 1st. The stock was purchased at an average cost of $12.37 per share, with a total value of $123,700.00. Following the acquisition, the director now directly owns 15,000 shares in the company, valued at $185,550. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Matrix Capital Management Comp bought 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, December 5th. The stock was purchased at an average price of $12.00 per share, with a total value of $15,000,000.00. Following the completion of the purchase, the insider now owns 5,362,870 shares in the company, valued at $64,354,440. The disclosure for this purchase can be found here. Insiders sold a total of 4,802 shares of company stock valued at $59,796 over the last 90 days. Insiders own 5.00% of the company's stock.
在Aura Biosciences的其他消息中,大股東Matrix Capital Management Comp在12月5日星期一的一筆交易中購買了125萬股該股。這些股票是以平均每股12.00美元的價格購買的,總價值為15,000,000.00美元。收購完成後,這位內部人士現在擁有該公司5,362,870股,價值64,354,440美元。此次收購是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在這個環節。其他消息方面,董事David邁克爾·約翰遜在一筆日期為12月1日(星期四)的交易中購買了10,000股該公司股票。這隻股票是以每股12.37美元的平均價格購買的,總價值為123,700.00美元。收購完成後,董事現在直接擁有該公司15,000股股份,價值18.555萬美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,大股東Matrix Capital Management Comp在12月5日星期一的一次交易中購買了125萬股該公司的股票。該股的收購均價為每股12.00美元,總價值為15,000,000.00美元。收購完成後,這位內部人士現在擁有該公司5,362,870股股份,價值64,354,440美元。關於這次購買的披露可以找到這裏。在過去的90天裏,內部人士總共拋售了4,802股公司股票,價值59,796美元。內部人士持有該公司5.00%的股份。
Institutional Trading of Aura Biosciences
Aura生物科學的制度性交易
Several institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SNC acquired a new position in shares of Aura Biosciences during the 3rd quarter worth about $105,000. American International Group Inc. raised its holdings in shares of Aura Biosciences by 208.3% during the second quarter. American International Group Inc. now owns 8,577 shares of the company's stock valued at $122,000 after acquiring an additional 5,795 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Aura Biosciences by 272.8% in the second quarter. JPMorgan Chase & Co. now owns 9,798 shares of the company's stock valued at $139,000 after acquiring an additional 7,170 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Aura Biosciences by 53.5% in the first quarter. Bank of America Corp DE now owns 11,857 shares of the company's stock worth $261,000 after acquiring an additional 4,131 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new stake in shares of Aura Biosciences during the second quarter worth approximately $190,000. Institutional investors and hedge funds own 55.63% of the company's stock.
幾家機構投資者最近調整了對該股的持股比例。法國巴黎銀行套利SNC在第三季度收購了價值約105,000美元的Aura Biosciences股票的新頭寸。美國國際集團(American International Group Inc.)在第二季度增持了208.3%的Aura Biosciences股票。美國國際集團(American International Group Inc.)在上個季度增持了5,795股後,目前持有該公司8,577股股票,價值12.2萬美元。摩根大通在第二季度將其對Aura Biosciences股票的持倉提高了272.8%。摩根大通(JPMorgan Chase&Co.)在上個季度增持了7,170股摩根大通股票後,目前持有該公司9,798股股票,價值13.9萬美元。今年第一季度,美國銀行(Bank Of America Corp DE)將其在Aura Biosciences的持股比例提高了53.5%。美國銀行DE目前持有11,857股該公司股票,價值261,000美元,此前該公司在上一季度增持了4,131股。最後,CapTrust Financial Advisors在第二季度購買了Aura Biosciences價值約19萬美元的新股份。機構投資者和對衝基金持有該公司55.63%的股票。
About Aura Biosciences
關於奧拉生物科學公司
(Get Rating)
(獲取評級)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
Aura Biosciences,Inc.是一家開發癌症治療方法的生物技術公司。該公司開發病毒樣藥物結合物(VDC)技術平臺,用於治療眼科和泌尿外科腫瘤學中高度未得到滿足的腫瘤。它開發了AU-011,一種治療原發脈絡膜黑色素瘤的VDC候選藥物。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- 免費獲取StockNews.com關於AURA生物科學的研究報告(AURA)
- 科技狗:是時候咬一口這些股票了
- 這筆收購會讓微軟成為熊市買入者嗎?
- 金塔拉治療公司是一顆隱藏的寶石嗎?
- 你應該熱身到Generac股票過冬嗎?
- 長期持有的3只高收益股利股票
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《奧拉生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aura Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。